AstraZeneca Fights Damages In Drug Pricing Suit
On the heels of a similar bid by Warrick Pharmaceuticals Corp., AstraZeneca Pharmaceuticals LP has rejected a request that it shell out treble damages to two classes in the average wholesale...To view the full article, register now.
Already a subscriber? Click here to view full article